marketcaparena

LTGO

Latigo Biotherapeutics, Inc.

Company overview

Market capitalization
$1.16B
Employees
—
Latest publication
2026-09-29

Financial statements

Income Quarterly

Exact reported values; units shown beside each amount. Missing values are —.
MetricQ2 20262026-06-30 · USD
Research Development21,226,000USD
Total Operating Expenses25,808,000USD
Net Income-25,797,000USD
SourceDisclosurePreliminary

Balance sheet Quarterly

Exact reported values; units shown beside each amount. Missing values are —.
MetricQ2 20262026-06-30 · USD
Total Assets64,760,000USD
Cash And Equivalents55,003,000USD
Total Current Assets59,199,000USD
Other Current Assets4,002,000USD
Other Non Current Assets3,801,000USD
Total Liabilities52,258,000USD
Total Current Liabilities51,575,000USD
Other Non Current Liabilities35,000USD
Total Stockholder Equity-276,080,000USD
Total Equity Including Noncontrolling Interest12,502,000USD
Property Plant Equipment Net1,760,000USD
Accounts Payable3,566,000USD
Short Term Debt705,000USD
Common Stock0USD
Retained Earnings-291,889,000USD
SourceDisclosureDeterministicFinal

Cash flow YTD

Exact reported values; units shown beside each amount. Missing values are —.
MetricQ2 20262026-06-30 · USD
Depreciation99,000USD
Stock Based Compensation4,121,000USD
Change To Liabilities-1,008,000USD
Change In Working Capital-4,513,000USD
Operating Cash Flow-48,350,000USD
Capital Expenditures-110,000USD
Investing Cash Flow-110,000USD
Financing Cash Flow33,949,000USD
Change In Cash-14,511,000USD
End Cash Flow55,210,000USD
SourceDisclosureDeterministicFinal

Operating metrics

No operating metrics are currently published for this company.

Revenue breakdown

No revenue breakdown is currently published for this company.

Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.